Rani Therapeutics Holdings (RANI) Non Operating Interest Expenses (2020 - 2026)

Rani Therapeutics Holdings has reported Non Operating Interest Expenses for 7 years, with the latest figure at $8000.0 in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses fell 99.09% year-over-year to $8000.0 in Q2 2026; TTM through Jun 2026 was $1.2 million, a 72.72% decrease from a year earlier, with the FY2025 full-year figure at $2.9 million, down 42.56% from the prior year.
• Non Operating Interest Expenses was $8000.0 for Q2 2026 at Rani Therapeutics Holdings, down from $88000.0 in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $1.3 million in Q3 2024, with the low at $8000.0 in Q2 2026.
• Average Non Operating Interest Expenses over 5 years is $885937.5, with a median of $1.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Non Operating Interest Expenses surged 72000.0% in 2022, then sank 99.09% in 2026.
• Over 5 years, Non Operating Interest Expenses stood at $719000.0 in 2022, then soared by 80.25% to $1.3 million in 2023, then decreased by 13.27% to $1.1 million in 2024, then tumbled by 69.13% to $347000.0 in 2025, then slumped by 97.69% to $8000.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $8000.0 (Q2 2026), $88000.0 (Q1 2026), and $347000.0 (Q4 2025), per Business Quant data.